- Home
- Publications
- Publication Search
- Publication Details
Title
Precision therapy for acute myeloid leukemia
Authors
Keywords
Acute myeloid leukemia, Precision therapy, Conventional chemotherapies, Molecular targeted inhibitors, Epigenetic mutations, Immunotherapy
Journal
Journal of Hematology & Oncology
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-01-05
DOI
10.1186/s13045-017-0543-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
- (2017) Mingxue Fan et al. Journal of Hematology & Oncology
- The leukaemia epigenome targeted
- (2017) Julie-Aurore Losman NATURE
- The road to precision oncology
- (2017) Andrew V Biankin NATURE GENETICS
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2 - and TET2 -Mutant Acute Myeloid Leukemia
- (2017) Alan H. Shih et al. Cancer Discovery
- AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
- (2017) Katharine Yen et al. Cancer Discovery
- All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
- (2016) Richard F. Schlenk et al. ANNALS OF HEMATOLOGY
- Chimeric antigen receptor T cell therapy in AML: How close are we?
- (2016) Saar Gill BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
- (2016) Lauren Y. Lee et al. BLOOD
- Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
- (2016) M. R. Luskin et al. BLOOD
- Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
- (2016) K. H. Metzeler et al. BLOOD
- PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation
- (2016) J C Albring et al. BONE MARROW TRANSPLANTATION
- Haematopoietic cell transplantation with and without sorafenib maintenance for patients withFLT3-ITD acute myeloid leukaemia in first complete remission
- (2016) Andrew M. Brunner et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genetic and epigenetic heterogeneity in acute myeloid leukemia
- (2016) Sheng Li et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
- (2015) Paolo Strati et al. AMERICAN JOURNAL OF HEMATOLOGY
- Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells
- (2015) M. P. Martelli et al. BLOOD
- Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells
- (2015) H. El Hajj et al. BLOOD
- Emerging therapeutic drugs for AML
- (2015) E. M. Stein et al. BLOOD
- Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification
- (2015) P. Strati et al. BLOOD
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients
- (2015) Brenda W. Cooper et al. Clinical Lymphoma Myeloma & Leukemia
- Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
- (2015) E. M. Lee et al. HAEMATOLOGICA
- Guadecitabine for AML and MDS: hype or hope?
- (2015) Mohamed A Kharfan-Dabaja LANCET ONCOLOGY
- Sorafenib and novel multikinase inhibitors in AML
- (2015) Naval Daver et al. LANCET ONCOLOGY
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
- (2015) Farhad Ravandi et al. LANCET ONCOLOGY
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
- (2015) Jean-Pierre J Issa et al. LANCET ONCOLOGY
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- Phase I dose escalation study of lestaurtinib in patients with myelofibrosis
- (2015) Elizabeth O. Hexner et al. LEUKEMIA & LYMPHOMA
- Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia
- (2015) Brunangelo Falini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy for Acute Myeloid Leukemia
- (2015) Felix S. Lichtenegger et al. SEMINARS IN HEMATOLOGY
- Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
- (2015) E. M. Lee et al. HAEMATOLOGICA
- Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation
- (2014) H. Celik et al. BLOOD
- Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
- (2014) J. E. Lancet et al. BLOOD
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
- (2014) H. Dohner et al. BLOOD
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia
- (2014) Robert K. Stuart et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
- (2014) Mark Kirschbaum et al. BRITISH JOURNAL OF HAEMATOLOGY
- Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
- (2014) Jean-Pierre Issa et al. CANCER
- Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges
- (2014) Michael Lübbert et al. CANCER
- Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
- (2014) Jorge E. Cortes et al. CANCER
- Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia
- (2014) Mark Levis Future Oncology
- Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
- (2014) Thomas Prebet et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia
- (2014) F Ravandi et al. LEUKEMIA
- Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
- (2014) I Pizzitola et al. LEUKEMIA
- Crenolanib is a selective type I pan-FLT3 inhibitor
- (2014) C. C. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FLT3 Inhibitors in AML: Are We There Yet?
- (2014) Akshay Sudhindra et al. Current Hematologic Malignancy Reports
- Chimeric Antigen Receptor Therapy for Cancer
- (2013) David M. Barrett et al. Annual Review of Medicine
- Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
- (2013) A. K. Burnett et al. BLOOD
- Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
- (2013) A. Galanis et al. BLOOD
- A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
- (2013) S. Nand et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- Tumor heterogeneity makes AML a “moving target” for detection of residual disease
- (2013) W. Zeijlemaker et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
- (2013) Roelof Willemze et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
- (2013) Casey B. Williams et al. PHARMACOTHERAPY
- The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
- (2013) Aziz Nazha et al. Frontiers in Oncology
- Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia
- (2012) Gautam Borthakur et al. CANCER
- New agents for acute myeloid leukemia: is it time for targeted therapies?
- (2012) Felicetto Ferrara EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Survival for older patients with acute myeloid leukemia: a population-based study
- (2012) B. Oran et al. HAEMATOLOGICA
- Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- (2012) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study
- (2012) Jerzy Holowiecki et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
- (2012) R M Stone et al. LEUKEMIA
- Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin
- (2012) M Kurimoto et al. LEUKEMIA
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia
- (2011) J.-H. Lee et al. BLOOD
- Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia
- (2011) Babu P. Mohan et al. BRITISH JOURNAL OF HAEMATOLOGY
- High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation
- (2011) M. S. De Propris et al. HAEMATOLOGICA
- Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
- (2011) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics
- (2011) Masanori Mori et al. LEUKEMIA RESEARCH
- Sorafenib Treatment in 13 Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations in Combination with Chemotherapy or as Monotherapy
- (2010) Thomas Schroeder et al. ACTA HAEMATOLOGICA
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
- (2010) H. Kantarjian et al. BLOOD
- Sorafenib bei rezidivierter und therapierefraktärer FLT3-ITD-positiver akuter myeloischer Leukämie: eine neue Behandlungsoption
- (2010) S Metzelder et al. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
- (2010) G. Borthakur et al. HAEMATOLOGICA
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
- (2010) Michel Duval et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation
- (2009) Sung Ho Lee et al. AMERICAN JOURNAL OF HEMATOLOGY
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
- (2009) K. W. Pratz et al. BLOOD
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
- (2009) A. K. Burnett et al. BLOOD
- PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
- (2009) L. Zhang et al. BLOOD
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
- (2009) Amanda F. Cashen et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- (2009) Hugo F. Fernandez et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
- (2009) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia
- (2008) N.N. Safaian et al. LEUKEMIA RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now